Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celltrion, Inc.
The first biosimilar approval stemming from Alvotech’s collaboration with JAMP Pharma in Canada has arrived, with the firms’ Simlandi (adalimumab) biosimilar version of AbbVie’s higher-strength Humira. Celltrion has also announced an approval from Health Canada.
The Pink Sheet takes a look back at major policy developments in South Korea in 2021 and ahead at what’s in store for the coming year.
Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.
After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.
- Generic Drugs
- OTC, Consumer
- Large Molecule
- Other Names / Subsidiaries
- Bio CDMO
- Celltrion Healthcare Hungary Kft